focus -WSS

focus

author：knowledge 2025-10-01 22:57:35 - browse：5118

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Free speech concerns arise in wake of journal editor Eisen's firing

WSS

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Senate panel clears PBM, hopsital reforms

MoonLake credibility takes another hit with mid

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

focus

focus

entertainment

Heart attack and stroke risk calculators need revising

Ambulance rides for just $100? Advisers want major billing fixes

Alkermes shareholders re

Wildfire pollution widens asthma inequities on Long Island

Alkermes shareholders re

Adults seen as increasingly susceptible to measles

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The Sacklers, horror, and ‘The Fall of the House of Usher’

The cancer drug shortage isn’t new — and neither are the solutions

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

leisure time

Medicare solvency divides Republicans at the presidential debate

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Scientists inch closer to single

Senate panel clears PBM, hopsital reforms

Biotech incubator Curie.Bio graduates its first startup

Vertex non

focus

explore

leisure time

knowledge